GlassScriptPhysician profile
Kimberly May
NPI 1396492757
$1,905.51
in general payments reported to CMS, 2019-2025
25 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $100 · 2024: $475 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,807 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,806.51 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $193.14 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $188.16 | 2025 | Veozah |
| Neurocrine Biosciences, INC. | $161.76 | 2024-2025 | Ingrezza |
| Amgen INC. | $161.62 | 2025 | Repatha, Otezla |
| Viiv Healthcare Company | $149.18 | 2025 | Dovato |
| Gilead Sciences, INC. | $117.46 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.23 | 2024-2025 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $100.23 | 2023 | |
| Lilly USA, LLC | $99.79 | 2025 | Mounjaro |
| Abbvie INC. | $85.41 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $72.04 | 2025 | Fanapt |
| Alkermes, INC. | $54.57 | 2024-2025 | Aristada, Vivitrol, Lybalvi |
| Exact Sciences Corporation | $50.51 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lundbeck LLC | $50.26 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.09 | 2024-2025 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.62 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $40.42 | 2025 | Qelbree |
| Dexcom, INC. | $39.33 | 2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $38.76 | 2024-2025 | Trelegy Ellipta |
| Abbott Laboratories | $22.28 | 2024 | Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $22.04 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $18.61 | 2024 | Austedo Xr |
| Merck Sharp & Dohme LLC | $16.65 | 2024 | Pifeltro, Delstrigo |
| Indivior INC. | $14.69 | 2025 | Sublocade |
| Noven Therapeutics, LLC | $13.66 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.